» Articles » PMID: 7768322

Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and Its Receptors: Neuroendocrine and Endocrine Interaction

Overview
Specialty Endocrinology
Date 1995 Jan 1
PMID 7768322
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

The recent progress of research on the functions of pituitary adenylate cyclase activating polypeptide (PACAP), especially endocrine and neuroendocrine interactions, is described. Studies of the genes encoding the PACAP precursor and the type I PACAP receptor provide information on the control of PACAP gene expression and on the relationship between the structure of the receptor subtypes and the activation of various signal transduction pathways. The availability of specific antisera against PACAP and the type I PACAP receptor made it possible to examine their distributions in the brain and other tissues. Immunohistochemical studies and physiological studies with synthetic PACAP indicate that PACAP is a new type of hypophysiotropic hormone and also functions as a neurotransmitter, neuromodulator, and neurotrophic factor in the central nervous system. The abundance of PACAP and its type I receptors in the adrenal medulla and the results of studies with synthetic PACAP suggest that PACAP is a potent noncholinergic secretogue for catecholamines. PACAP and its receptors are also present in the pancreas and appear to play a regulatory role in insulin secretion at extremely low concentrations in a glucose-dependent manner. Immunohistochemical demonstration of PACAP and its receptors in the testicular spermatids at early stages suggests an important role of testicular PACAP in spermiogenesis. Together with its actions on pituitary gonadotropes, this suggests that it plays a key role in reproduction.

Citing Articles

Same same, but different: exploring the enigmatic role of the pituitary adenylate cyclase-activating polypeptide (PACAP) in invertebrate physiology.

Pirger Z, Urban P, Galik B, Kiss B, Tapodi A, Schmidt J J Comp Physiol A Neuroethol Sens Neural Behav Physiol. 2024; 210(6):909-925.

PMID: 38940930 PMC: 11551080. DOI: 10.1007/s00359-024-01706-5.


Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders.

Karsan N, Edvinsson L, Vecsei L, Goadsby P Ann Clin Transl Neurol. 2024; 11(7):1654-1668.

PMID: 38887982 PMC: 11251486. DOI: 10.1002/acn3.52119.


Pleural mesothelioma from fluoro-edenite exposure: PACAP and PAC1 receptor. A preliminary report.

Lombardo C, Maugeri G, DAmico A, Broggi G, Caltabiano R, Filetti V Eur J Histochem. 2024; 68(2).

PMID: 38699968 PMC: 11110723. DOI: 10.4081/ejh.2024.3994.


PAC1 deficiency reduces chondrogenesis in atherosclerotic lesions of hypercholesterolemic ApoE-deficient mice.

Blumm C, Bonaterra G, Schwarzbach H, Eiden L, Weihe E, Kinscherf R BMC Cardiovasc Disord. 2023; 23(1):566.

PMID: 37980508 PMC: 10657554. DOI: 10.1186/s12872-023-03600-5.


PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection During Cisplatin Chemotherapy.

Li S, Huang J, Guo Y, Wang J, Lu S, Wang B Front Immunol. 2021; 12:714244.

PMID: 34552585 PMC: 8450570. DOI: 10.3389/fimmu.2021.714244.